“CB1 Pharmacy Announces Supply Agreement with Xeal Pharma for EcoCann Access Cannabis-Based Products for Medicinal Use in the UK”
After receiving positive feedback from patients, CB1 Pharmacy has entered into a supply agreement with Xeal Pharma for their EcoCann Access line of Cannabis-Based Products for Medicinal Use (CBPM). These products are derived from Glass Pharms’ UK-grown medical cannabis flower.
CB1 Pharmacy has a strong focus on affordability and accessibility for eligible patients, and the addition of EcoCann Access to their prescribed products further supports this commitment. The EcoCann Access range offers cost-effective options for CBPM, with a fully UK-based supply chain that is open to all patients registered with any current access scheme.
CB1 Medical, the launch partner for the EcoCann Access range, offers prescribing options organized around cannabis phenotypes, rather than individual cultivars. The range will include a constant availability of Sativa, Indica, and Balanced Hybrid types, providing clinicians with the option to maintain continuity across phenotypes. Patient and clinician information will also include a list of specific cultivars from which the CBPM is derived.
James Duckenfield, CEO of Glass Pharms, stated, “Although cannabis phenotypes are not an exact science, they are still a useful way of determining the general indication of a cannabis-based medicine. These are often described as ‘day-time’ and ‘night-time’ options by patients and clinicians. The effects seem to be determined by the type of terpene content, which broadly maps onto the general phenotype.”
The specific cultivars in the range may change over time, but the EcoCann Access range will provide a simpler option for patients and clinicians who may find navigating the world of cannabis cultivars confusing.
“We recognize the importance of a UK-based supply chain and are pleased to partner with Glass Pharms on a range of products derived from their flower. This will increase accessibility and choice for UK patients,” said Professor Rishabh Prasad, Founder of CB1 Medical.
Irfan Abdulla, CB1 Pharmacy’s Superintendent Pharmacist, added, “Having seen Glass Pharms myself, I can attest to their use of the most robust processes to maintain the highest quality medicine.”
Glass Pharms is a leading cultivator of medical cannabis, utilizing a custom-built 2.4-hectare greenhouse facility in the West of England. Their operations are powered entirely by food waste, making them a leader in sustainability within the industry.
CB1 Medical, known as the “UK’s most affordable medical cannabis clinic,” is a rapidly growing private medical cannabis clinic that follows a patient-led care model.
For more information on Glass Pharms and CB1 Medical, please visit their websites at https://glasspharms.com/ and https://cb1medical.com/. For any inquiries, please contact info@glasspharms.com.
This press release is distributed by https://pressat.co.uk/.
